Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Advanced Solid Tumor × sintilimab × Clear all

Phase

Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 4 Stomach Neoplasms 2 Small Cell Lung Carcinoma 1 Neoplasms 1 Liver Neoplasms 1 Hepatoblastoma 1 Endometrial Neoplasms 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 camrelizumab 1 atezolizumab 1 anlotinib 1 Inosine 1 Injections 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Beijing Friendship Hospital

Phase 2/3 Completed

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡